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Mononuclear phagocytes (bone marrow monocyte-derived macrophages, alveolar macrophages, perivascular macrophages, and microglia) are
reservoirs and vehicles of dissemination for the human immunodeficiency virus type-1 (HIV-1). How virus alters mononuclear phagocyte
immunoregulatory activities to complete its life cycle and influence disease is incompletely understood. In attempts to better understanding the
influence of virus on macrophage functions, we used one-dimensional electrophoresis, and liquid chromatography tandem mass spectrometry to
analyze the secretome of HIV-1-infected human monocyte-derived macrophages. We identified 110 proteins in culture supernatants of control
(uninfected) and virus-infected cells. Differentially expressed cytoskeletal, enzymes, redox, and immunoregulatory protein classes were
discovered and validated by Western blot tests. These included, but were not limited to, cystatin C, cystatin B, chitinase 3-like 1 protein, cofilin-1,
L-plastin, superoxide dismutase, leukotriene A4 hydrolase, and α-enolase. This study, using a unique proteomics platform, provides novel insights
into virus–host cell interactions that likely affect the functional role of macrophages in HIV disease.
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doi:10.1016/j.virol.2007.01.013comprise the principal elements in the clearance and inactiva-
tion for microbial pathogens. Paradoxically, these same cells
represent the major target and infectious reservoir for HIV-1
(Bhoopat et al., 2006; Collman et al., 2003; Gartner et al., 1986;
Gendelman and Morahan, 1992; Gendelman et al., 1989;
Meltzer and Gendelman, 1992). In distinct ways, HIV alters
MP's innate and adaptive immune functions enabling the virus
to persist for long time periods (Kramer-Hammerle et al., 2005;
Maslin et al., 2005; Olivetta and Federico, 2006; Palmieri et al.,
2004). As a result of circumventing cell-based anti-retroviral
mechanisms, reservoirs for HIVare established in bone marrow
progenitor cells, circulating monocytes, alveolar and perivas-
cular macrophages, and microglia (Collman et al., 2003;
Pomerantz, 2004). Defective phagocytic, intracellular killing,
secretory activity, and antigen presentation have been reported
in monocytes recovered from virus-infected individuals or
Table 1
Levels of reverse transcriptase (RT) activity in six culture supernatants
Donor RT×104
1 2 3 4 5 6
Days 1 ND ND ND ND ND ND
2 – – – 29.72
3 – – – 46.61 11.42 18.21
5 – – – 6.50 13.27 47.71
7 5.43 44.32 52.73 3.90 32.23 52.76
9 14.53 85.12 44.35 – 34.95 57.16
12 17.30 64.02 36.61 – – –
14 15.81 49.24 20.46 – – –
ND=not detected; –=not tested.
Fig. 1. Cytopathic effects of HIV-1ADA-infected MDM. (A) Photographs of
MDM culture infected with HIV-1 showing progressive MNGC formation from
initiation of infection to day 10. (B) An index of the number of nuclei per cell
increases along with culture progression and secondary infection of cells that
were not infected during initial exposure to the virus.
199P. Ciborowski et al. / Virology 363 (2007) 198–209following in vitro infections (Capsoni et al., 1992; Evans and
Wansbrough-Jones, 1996; Gordon and Read, 2002; Kedzierska
and Crowe, 2002; Zhou et al., 1998).
MP–virus interactions and immune activation ultimately
leads to tissue destruction. This is commonly seen in the brain,
gut, lung, and spinal cord where MP-soluble factor secretion
contributes to viral spread and host tissue injury and inflamma-
tion (Ansari, 2004; Giulian et al., 1990; Gordon and Read, 2002;
Gupta and Gollapudi, 1993; Ichikawa et al., 2003; Kaul et al.,
2005; Lim et al., 1993; McArthur et al., 2005; Satomi et al.,
2005; Stevenson and Gendelman, 1994). The latter events can
occur by inducing cell death or changes in immune and
homeostatic functions as a result of cell secretions. The
functional and biological outcomes of HIV-1 MP infection
also hinge on cell differentiation, as the viral life cycle is
dependent on it. Understanding how such events occur is pivotal
in understanding how virus can affect disease while at the same
time overcome potent innate anti-retroviral immune responses.
After entering tissue, monocytes differentiate into macro-
phages where they maintain homeostasis, eliminate microbial
pathogens, and clear debris. At the same time the cells respond
to a variety of environmental cues. These with infection itself,
lead to the upregulation of secreted pro-inflammatory cyto-
kines, reactive oxygen species, quinolinic acid, glutamate,
arachidonic acid, and its metabolites. How cellular factors
contribute to a wide range of “primary”HIV-associated diseases
is a subject of intense research (Colton, 1994; Colton and
Gilbert, 1987; Gelbard et al., 1994; Klegeris and McGeer,
1997). To gain a better understanding of the impact by which
HIV-infected macrophages affect its environment we profiled
its secreted proteins. A foundation for these studies was made
through the establishment of an initial list of both the human
macrophage proteome and secretome (Dupont et al., 2004; Mor-
Vaknin et al., 2003). We posit that HIV-1-infected macrophages
could affect protein abundance expressed at otherwise very low
levels and under normal physiological conditions. Therefore,
our study was designed to profile secretome of infected
monocyte-derived macrophages (MDM) and compare the
profiles seen with uninfected cells. The intent of these works
was to discover proteins that are linked to disease and could, in
some manner, be applied as biomarkers for disease.
To achieve these goals, we utilized one-dimensional
separation (1D SDS–PAGE) and MS/MS to identify MDMproteins secreted as a consequence of HIV-1 infection.
Differential expression of selected proteins was further
validated using Western blot analysis. Presented data provide
novel insights into the delicate homeostatic changes within the
macrophage evolving from persistent viral replication and
cytopathicity.
Results
After 7 days in culture, human monocytes differentiate into
macrophage-like cells and readily elicit productive infection
following exposure to the macrophage tropic viral strain HIV-
200 P. Ciborowski et al. / Virology 363 (2007) 198–2091ADA. Productive HIV-1 replication was demonstrated by RT
activity and reflected progeny virion production released into
culture fluids from the infected macrophages (Table 1)
(Gendelman et al., 1988). Another measure of progressive
viral infection is formation of multinucleated giant cells
(MNGC) expressed as a ratio of the number of nuclei per cell,
also called giant cell index (GCI). Fig. 1A illustrates
photomicrographs of control and HIV-1-infected MDM. Fig.
1B depicts the GCI index. Formation of MNGC occurs as early
as 3 days after infection. On day 10 most MDM form large
syncytia. Kinetics, but not susceptibility, of progression of HIV-
1 infection is donor-dependent. In contrary to T-cells, which are
susceptible to apoptosis shortly after being infected with HIV-1,
macrophages are more resistant to cell death and continuously
support viral replication (Vazquez et al., 2005; Wahl et al.,
1996). HIV has been reported to turn-off macrophage apop-
totic pathways following infection (Greenway and McPhee,
1997).
Culture supernatants were collected at days 2, 3, 5, 7, 9, 12,
and 14 after infection. Removal of the viral inoculum 24 h
after infection was performed by three consecutive rinses.
These multiple rinses also removed any proteins that were
introduced into the culture with viral inoculum during the
initial period of infection. Typically, protein concentration inFig. 2. 1-DE SDS–PAGE analysis of secreted proteins from MDM culture supernatan
of protein were loaded per lane. 1-DE SDS–PAGE analysis of secreted proteins before
α-trypsin, haptoglobin, and transferrin. (B) Samples of 60 μg of protein were loaded p
was removed.culture supernatants of HIV-1-infected MDM was ∼50%
higher than what was observed in controls (data not shown).
This difference could reflect changes in cell metabolism.
Proteomic analyses were performed on selected culture fluids
collected at maximal RT levels which coincided with
substantial HIV-1p24 protein secreted into the culture fluids
(Fig. 4). This varied amongst donors between days 3 and 9.
Although in one instance the RT level was highest on day 12,
this and later time points were excluded as cytosolic proteins
from dying cells could be present in culture fluids (Kadiu et
al., 2006).
Despite exchanges of media with serum-free DMEM prior to
sample collection residual serum albumin, immunoglobulins,
and/or other most abundant serum proteins were present and
likely retained on the cell surface. A representative 12% PAGE
gel 24-cm-long gel was arbitrarily divided to 20 bands indicated
by black boxes (Fig. 2A). Proteins from 20 gel cubes were
subjected to in-gel trypsin digestion and subsequently identified
by liquid chromatography tandem mass spectroscopy (LC–MS/
MS). Table 2 lists 83 proteins identified within high confidence
limits. For database searches Seaquest algorithm (Bioworks
3.1SR software, ThermoElectron, Inc.) was employed. Listed
proteins represent data combined from four independent
experiments. Results of database searches were filtered andts. Gels were stained with SyproRuby® fluorescent dye. (A) Samples of 100 μg
and after removal of six most abundant proteins: serum albumin, IgG, IgA, anti-
er lane. Black box shows the region which was re-analyzed after serum albumin
Table 2
Proteins identified in secretome of HIV-1-infected and control MDM (LC–MS/MS identification)
Protein NCBI a SwissProt b MW Postulated function
HIV 14-3-3 gamma protein 5726310 P61981 28,171 Signal transduction, cytoskeletal organization and biogenesis
HIV 14-3-3 protein zeta/delta 33872678 P63104 27,745 Transcription factor binding
HIV 14-3-3 protein/cytosolic phospholipase A2
3-monooxygenase/tryptophan
5-monooxygenase
4262000 Q6LD62 7957 Protein domain-specific binding
HIV Activation protein 31543976 P61981 28,171 Regulation of mitosis, regulation of signal transduction
COM Actin various forms c c c
COM Aldolase A protein 28595 P04075 39,289 Fructose-bisphosphate aldolase activity, catalytic activity
COMd Alpha 2 macroglobulin 46812315 P01023 163,278 Intracellular protein transport
COM Alpha enolase 2661039 P06733 47,038 Phosphopyruvate hydratase activity, plasminogen activator activity
COMd Alpha-1 antitrypsin 28637 Q13747 22,828 Serine-type endopeptidase inhibitor activity chaperone-mediated
protein complex assembly, acute-phase response
COM Amyloid P component, serum 30582339 P02743 25,387 Protein folding
COM Annexin A2 16306978 P07355 38,473 Phospholipase inhibitor activity
COM Apo-B100 precursor 28780 P04114 515,563 Lipid transporter activity, receptor binding
COMd Apolipoprotein A-I 37499465 Q6Q785 30,778 Lipid transporter activity, protein binding
COMd Apolipoprotein A-II preproprotein
[Homo sapiens]
4502149 P02652 11,175 Lipid transporter activity, protein binding
COM Apolipoprotein A-IV precursor [Homo sapiens] 178757 P06727 45,371 Lipid transporter activity, protein binding
N Apolipoprotein C-II precursor [Homo sapiens] 32130518 P02655 11,284 Lipoprotein lipase activity
N Apolipoprotein C-III precursor [Homo sapiens] 4557323 P02656 10,852 Lipoprotein lipase activity
COM Apolipoprotein D precursor [Homo sapiens] 4502163 P05090 21,276 Lipid metabolism, transport
COM Apolipoprotein E precursor [Homo sapiens] 4557325 P02649 36,154 Lipid transporter activity, lipid binding, tau protein binding
COM Apolipoprotein H (beta-2-glycoprotein I)
[Homo sapiens]
32165624 P02749 38,298 Lipid transporter activity, heparin binding
HIV Cap-G [Homo sapiens] 63252913 P40121 38,518 Actin binding
COM Cathepsin B preproprotein [Homo sapiens] 22538437 P07858 37,822 Intracellular degradation and turnover of proteins
HIV Cathepsin D preproprotein [Homo sapiens] 4503143 P07339 44,552 Aspartic-type endopeptidase activity
HIV Cathepsin S [Homo sapiens] 179957 P25774 37,510 Cysteine-type endopeptidase activity
COM Ceruloplasmin (ferroxidase)
[Homo sapiens]
4557485 P00450 122,205 Ferroxidase activity, copper ion transporter activity,
oxidoreductase activity extracellular matrix structural constituent,
hydrolase activity hydrolyzing O−
COM Chitinase 3-like 1 [Homo sapiens] 25058041 P36222 42,613 Glycosyl compounds, chitinase activity
HIV Cofilin-1 (non-muscle) [Homo sapiens] 30582531 P23528 18,371 Actin binding, protein binding
HIV Cofilin-2 [Homo sapiens] 33946278 Q9Y281 18,737 Protein binding
COM Cystatin B (stefin B) [Homo sapiens] 68783 Q76LA1 11,140 Endopeptidase inhibitor activity, cysteine protease
inhibitor activity
N Cystatin C precursor [Homo sapiens] 4503107 P01034 15,799 Cysteine protease inhibitor activity, protein
homodimerization activity
HIV Cytosolic malate dehydrogenase
[Homo sapiens]
5174539 P40925 36,295 Oxidoreductase activity; malate dehydrogenase activity
HIV Cytovillin 2 [Homo sapiens] 6063151 Q9UJZ2 18,419 Cytoskeletal protein binding
HIV Ezrin [Homo sapiens] 6063147 Q9UJZ6 19,237 Cytoskeletal protein binding
HIV Filamin [Homo sapiens] 1203969 P21333 280,761 Actin binding
HIV Filamin-2 [Homo sapiens] 8885790 Q14315 290,959 Actin binding
HIV Filamin-A [Homo sapiens] 53791221 Q60FE5 278,226 Actin binding
N FNHU fibronectin precursor [validated] – human 279675 P02751 262,607 Extracellular matrix structural constituent, protein binding
HIV Fructose-1,6-bisphosphates [Homo sapiens] 3293553 36,683 36,683 Carbohydrate metabolism
HIV gag protein [Human immunodeficiency virus 1] 55416335 e e
HIV gag protein [Human immunodeficiency virus 1] 33145913 e e
HIV gag protein [Human immunodeficiency virus 1] 33145909 e e
HIV gag–pol polyprotein [Human immunodeficiency
virus 1]
21671035 e e
COM Gelsolin isoform a [Homo sapiens] 4504165 P06396 85,697 Actin filament polymerization, calcium ion binding
COM Gelsolin isoform b (cytoplasmic) [Homo sapiens] 38044288 P06396 85,698 Actin filament polymerization, calcium ion binding
HIV Glutathione S-transferase omega 1-1 [Homo sapiens] 55925946 Q5TA03 27,566 Glutathione transferase activity
HIV Glyceraldehyde-3-phosphate dehydrogenase
[Homo sapiens]
31645 P04406 35,922 Glyceraldehyde-3-phosphate dehydrogenase
(phosphorylating) activity
COM GM2-activator protein [Homo sapiens] 31857 P17900 20,822 Sphingolipid activator protein activity
COMd Haptoglobin [Homo sapiens] 1620396 P00739 39,008 Serine-type endopeptidase activity, hemoglobin binding
COMd Haptoglobin [Homo sapiens] 3337390 P00738 45,205 Serine-type endopeptidase activity, hemoglobin binding
N Histidine-rich glycoprotein precursor [Homo sapiens] 4504489 P04196 59,578 Cysteine protease inhibitor activity, heparin activity
HIV hp2-alpha [Homo sapiens] 296653 Q6LBY9 41525 Serine-type endopeptidase activity, hemoglobin binding
(continued on next page)
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Protein NCBI a SwissProt b MW Postulated function
HIV Human thioredoxin 1827674 P52566 11,705 Rho GDP-dissociation inhibitor activity
HIV ITH4_HUMAN Inter-alpha-trypsin
inhibitor heavy chain H4 precursor
13432192 Q14624 103,358 Endopeptidase inhibitor activity
COM Lactate dehydrogenase A [Homo sapiens] 5031857 Q6ZMR3 36,507 L-Lactate dehydrogenase activity, oxidoreductase activity
HIV Lactate dehydrogenase B [Homo sapiens] 4557032 Q9BYZ2 41,979 L-Lactate dehydrogenase activity
HIV L-Lactate dehydrogenase 34527427 P00338 36,558 L-Lactate dehydrogenase activity
HIV Macrophage capping protein 21730367 P40121 38,524 Actin binding
COM MMP9 [Homo sapiens] 10443048 P14780 78,427 Macrophage differentiation, metalloendopeptidase activity
HIV Moesin [Homo sapiens] 4505257 P26038 67,689 Cytoskeletal protein binding
HIV NADP-dependent isocitrate dehydrogenase
[Homo sapiens]
11374664 O75874 46,659 Isocitrate dehydrogenase (NADP+) activity
COMd Orosomucoid 1, precursor
[Homo sapiens]
20070760 P02763 23,512 Modulating the activity of the immune system during the
acute-phase reaction
COMd Orosomucoid 2 [Homo sapiens] 4505529 Q5T538 23,603 Signal transduction
COM Peroxiredoxin 1 55959887 Q06830 22,110 Oxidoreductase activity, peroxidase activity, antioxidant activity
HIV Phosphoglycerate kinase 1 [Homo sapiens] 4505763 P00558 44,483 Phosphoglycerate kinase activity
COM PREDICTED: similar to FKSG30 51493213 Q9BYX7 42,016 Structural constituent of cytoskeleton, protein binding,
ATP binding
COM Profilin-1 30582841 Q53Y44 15,054 Cytoskeleton organization and biogenesis
HIV Proteasome activator subunit 1 5453990 Q06323 28,723 Proteasome complex
HIV Proteasome activator subunit 2 30410792 Q9UL46 27,230 Proteasome complex
HIV Prothymosin alpha [Homo sapiens] 307352 Q15203 8161 Unknown
HIV Rho GDP dissociation inhibitor beta
[Homo sapiens]
20379030 P52566 22,988 Rho GDP-dissociation inhibitor activity endopeptidase inhibitor
activity, serine-type endopeptidase inhibitor activity
COM Serine (or cysteine) proteinase inhibitor 30584253 P01009 55,299 Protein binding
N SH3 domain binding glutamic acid-rich
protein like 3 [Homo sapiens]
55960189 Q5T123 9381 Secreted protein
HIV smooth muscle and non-muscle myosin alkali light
chain isoform 1–4
17986262 P60660 16,799 Motor activity; calcium ion binding
N Superoxide dismutase [Homo sapiens] 27065835 P00441 15,805 Superoxide dismutase activity
HIV Transaldolase 1 [Homo sapiens] 5803187 P37837 37,540 Carbohydrate metabolism
COMd Transferrin 37747855 P02787 77,050 Ion transport; iron ion binding
HIV Transferrin receptor 4507457 P02786 84,901 Transferrin receptor activity
HIV Triosephosphate isomerase 1 17389815 P60174 26,538 Triose–phosphate isomerase activity
HIV Tropomyosin 3 55665780 Q5VU59 27,175 Cytoskeletal protein binding
HIV Tropomyosin 4 12803959 P67936 28,391 Cytoskeletal protein binding
COM TTR 48145933 Q6IB96 15,873 Thyroid hormone-binding protein tyrosine 3/tryptophan
5-monooxygenase activation
HIV Protein 21735625 P63104 27,745 Transcription factor binding
HIV VIM 47115317 P08670 53,520 Protein binding; structural constituent of cytoskeleton
HIV – infected; N – uninfected; COM – common.
a NCBI Accession Numbers.
b SwissProt Accession Numbers.
c Multiple accession numbers of various forms (including fragments) were obtained from database searches.
d Top 12 most abundant proteins found in human serum.
e For details see Table 3.
Table 2 (continued)
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exceeded the criteria of Unified Score of 3000 with Sp>500,
XCorr>2.5 for doubly charged and 3.5 for triply charged
precursor ions, and Delta Cn>0.3. Identification of protein
within high confidence limits was accepted as positive when a
minimum of two peptides were sequenced meeting established
criteria in at least two independent experiments. Peptides ofTable 3
LC–MS/MS identified HIV-1 proteins and found in culture supernatants of HIV-1-s
Protein NCBI Accession Number Pep
Reverse transcriptase gi||55709508|gb|AAV58679.1| [55709508] YQ
Envelope glycoprotein gi|62906511|gb|AAY20909.1| [62906511] QA
Gag protein gi|5668939|gb|AAD46087.1| AF077336_1[5668939] QL30 amino acids or longer with scattered y- or b-series ions that
had assigned the Unified Score greater than 3000 but low XCorr
and Delta Cn values were excluded. HIV-1 peptides were poorly
fragmented by LC–MS/MS and only few were sequenced
(Table 3), which can result from either incomplete trypsin
fragmentation or poor ionization. Serum albumin and immu-
noglobulins were excluded from the summary of Tables 2 and 4.ecreted proteins
tide sequence MH+ z XCorr Delta Cn
YNVLPMGWXGSPAIFQSSMTXVLEPFR 3346.90 3 2.621 0.322
YCNINATEWNNTLQEVGRELEK 2825.06 3 2.937 0.353
QPSLQTGSEELK 1558.72 2 3.920 0.397
Table 4
Proteins identified in the range of 50 to 60 kDa in 1-DE after removal of six most abundant proteins
Protein NCBI a SwissProt b MW Postulated functions
N Alpha 2 macroglobulin 46812315 P01023 163,278 Endopeptidase inhibitor activity, enzyme binding, IL-1 binding,
IL-8 binding, TNF binding, protein homooligomerization
HIV ATPase, H+ transporting,
lysosomal 70 kDa
15341906 P38606 68,304 Proton-transporting two-sector ATPase complex
HIV BiP 1143492 P11021 72,333 ATP binding, calcium ion binding, caspase inhibitor activity,
negative regulation of caspase activity, anti-apoptosis
COM Complement component 3 40786791 P01024 187,164 G-protein-coupled receptor protein signaling pathway,
immune response, signal transduction
COM Gelsolin 38044288 P06396 85,698 Actin filament polymerization, actin filament severing, barbed-end
actin filament capping
HIV Heat shock 70 kDa protein
8 isoform 2
24234686 Q53HF2 53,500 ATP binding, nucleotide binding, protein folding, response to
unfolded protein
HIV Heat shock 90 kDa protein 1,
alpha
83699649 Q2PP14 98,143 ATP binding, nitric oxide synthase regulator, protein homodimerization,
TPR domain binding, mitochondrial trans-regulation of nitric oxide
biosynthesis, protein refolding, signal transduction
HIV Heat shock 90 kDa protein 1,
beta
56204416 Q5T9W7 83,264 Nitric oxide synthase regulator, TPR domain binding, positive
regulation of nitric oxide biosynthesis, protein refolding, unfolded protein
HIV Heat shock protein 4204880 P54652 70,021 Unfolded protein binding, male meiosis, response to unfolded protein,
spermatid development
HIV HSP70-2 4529892 P08107 70,052 Anti-apoptosis, mRNA catabolism, response to unfolded protein
HIV Interferon-induced Mx protein 4505291 P20591 75,403 GTP binding, defense response, induction of apoptosis, signal transduction
HIV IQGAP1 protein 40674640 Q6P1N4 107,539 Mediates VE-cadherin-based cell–cell contacts and VEGF signaling
at adherence junctions
HIV Karyopherin beta 1 19923142 Q14974 97,170 Zinc ion binding, NLS-bearing substrate import into nucleus,
protein import into nucleus, translocation
COM Leukotriene A4 hydrolase 4505029 P09960 69,154 Epoxide hydrolase activity, peptidase activity, zinc ion binding,
inflammatory response, leukotriene biosynthesis
COM L-Plastin 14043359 P13796 70,289 Actin binding, calcium ion binding
HIV MARCKS protein 33877895 Q6NVI1 14,859 Interacts with the metabotropic glutamate receptor type 7 and
modulates G protein-mediated constitutive inhibition
COM Matrix metalloproteinase 9 22532481 P14780 78,427 Collagenase activity, gelatinase B activity, zinc ion binding,
macrophage differentiation
HIV Moesin 5419633 P26038 67,689 Structural constituent of cytoskeleton, cell motility, receptor binding
HIV Myristoylated alanine-rich
protein kinase C substrate
56203645 P29966 31,423 Actin filament binding, calmodulin binding
HIV Radixin 28436809 P35241 68,564 Binding barbed end of actin filaments, binds SLC9A3R1
HIV SEC23-related protein A 38202214 Q15436 86,147 Vesicle-mediated transport
N Transferrin receptor 4507457 P02786 84,901 Transferrin receptor, activity iron ion homeostasis
COM Transketolase 31417921 Q53EM5 67,906 Oxygen-independent glucose metabolism
HIV UNC-112-related protein 2
long form
41281905 Q86UX7 75,953 Cell adhesion
HIV Vacuolar sorting protein 35 9622850 Q96QK1 91,707 Retrograde transport, endosome to Golgi
HIV Villin 2 (ezrin) 66347778 Q4VX75 69,413 Cytoskeletal protein binding
HIV Zyxin 58530845 Q15942 61,277 Cell adhesion, cell–cell signaling, signal transduction
HIV – infected; N – uninfected; COM – common.
a NCBI Accession Numbers.
b SwissProt Accession Numbers.
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with human serum are marked in Table 2 with “d”.
Two “intensely” stained protein bands ∼49 and 25 kDa (Fig.
2A) represented serum albumin and heavy and light chains of
immunoglobulins (data not shown) in concentrated samples.
Therefore, we removed albumin and the other five proteins
(IgG, IgA, anti-α-trypsin, haptoglobin, and transferrin) from the
samples and this region was re-analyzed (Fig. 2B). After
removal of highly abundant proteins, another 27 proteins were
identified by LC–MS/MS. One of them, L-plastin, was signi-
ficantly upregulated in HIV-1-infected MDM fluids. Table 4
shows the summaries of identified proteins. The total number of
identified proteins was 110.Although our proteomic approach was not quantitative per
se, we observed differences in the relative abundance of peptides
sequenced by LC–MS/MS. This indicated that these proteins
could be differentially expressed as a result of viral infection.
Based on this interpretation we performed quantitative Western
blot analysis in order to confirm our LC–MS/MS results. This
strategy was applied successfully in our previous works
(Ciborowski et al., 2004). A few examples of differentially
expressed proteins are worth noting. Mass spectrometry
indicated cystatin C as differentially expressed and found in
culture supernatants of uninfected MDM, but not in infected
cells (Table 2). Although Western blot analysis detected the
protein in both control and infected MDM, cystatin C was
204 P. Ciborowski et al. / Virology 363 (2007) 198–209downregulated in infected cells making it concordant with mass
spectrometry data. Cofilin-1 was found upregulated in infected
MDM by mass spectrometry and confirmed by Western blot
tests (Fig. 3). Using the same paradigm, six differentially ex-
pressed proteins were found. This included cystatin B, cystatin
C, L-plastin, leukotriene A4 hydrolase (LTA4H), α-enolase, and
chitinase 3-like 1 protein (HC-gp39). HIV-1 p24 included in
Fig. 3 served as an internal control and substantiating virus
production. Among selected proteins, levels of HC-gp39 were
decreased, and L-plastin, LTA4H and α-enolase were increased
following HIV-1 infection. The exception was superoxide
dismutase (SOD), a protein shown to be upregulated in HIV-
infected MDM and confirmed by Western blot tests although
LC–MS/MS showed conflicting results. We posit that such
results were seen as SOD co-migrates with other identified
proteins such as cofilin-1 and cystatin B when analyzed on 1D
SDS–PAGE. Thus, protein co-migration may lead to such
discrepancies between LC–MS/MS and Western blot results.
As mentioned above, the dynamic of viral infection will vary
from donor to donor. In consequence, levels of differentially
expressed proteins will vary and give rise to substantive standard
deviations amongst data sets. Nevertheless, our densitometry
analyses (Fig. 4) demonstrated that with the exception of
LTA4H, all proteins showed consistent trends in expression with
many time points being different with statistical significanceFig. 3. Western blot analysis of HIVp24, cystatin B, cystatin C, cofilin-1,
L-plastin, SOD, LTA4H, α-enolase, and HCgp-39 in culture supernatants
of a representative experiment. Samples of culture supernatants from HIV-1ADA-
infected and control MDM (5 to 25 μg of protein per lane) were loaded on 4–
12% NuPAGE gel. Separated proteins were electroblotted onto PVDF
membrane and immunodetected as described in Materials and methods.(p<0.05) and are marked with “*”. We also expect that
differential expression of more proteins will be identified
using this strategy enhanced by additional steps of sample
preparation and fractionation.
Discussion
HIV-1-infected MPs affect the human host, including, most
prominently, neuronal dysfunction. This occurs by inflamma-
tory factors and viral protein secretions (Giulian et al., 1993).
Nonetheless, little is known about how viral infection triggers
immunomodulatory mechanisms affecting its function in
disease. The mechanisms of MNGC formation are also not
well understood. To gain a better understanding of macrophage
function as a consequence of HIV-1 infection, we used profiled
secreted proteins by proteomics tests. Our results show that the
majority of differentially expressed proteins reported in this
study represent a wide range of functional groups and include
structural (cytoskeleton), redox, regulatory, and enzymes. In
some instances one protein was included in two groups as SOD
is an enzyme and is an important component of redox regulatory
mechanisms. It is important to note that following HIV-1
infection, the macrophage is stimulated and the number of
secreted proteins increased. This observation supports the
notion that the virus accelerates production and secretion of
macrophage proteins to its advantage, and perhaps represents a
coping mechanism to best contain ongoing viral replication.
Using Western blot analysis, we confirmed differential
expression of a number of proteins, which could be linked to
viral replication. The roles of these proteins in HIV-1 macro-
phage infection are not yet fully understood and their contri-
bution to disease can now only be speculated. With regards to
HIV-1-associated cognitive impairment, it is well known that
virus-infected macrophages and microglia directly contribute to
disease as a consequence of inflammatory toxic secretions
(Kadiu et al., 2005). The nature of these factors and their relative
contribution to disease is complex and involves interactions
between primary neuronal cells, glia and blood-borne macro-
phages (Rostasy, 2005).
Many proteins identified in this study are directly involved or
associated with MP inflammatory responses. SOD follows
macrophage activation as it is regulated by pro-inflammatory
cytokines and independent of substrate concentrations (Ferlat
and Favier, 1993; Marikovsky et al., 2003). If mechanism of
SOD and other redox enzymes goes out of delicate balance,
macrophage are unable to control the levels of toxic radical
species which leads to tissue injury. Decreased levels of cystatin
C in culture supernatants of in vitro HIV-1-infected MDM
correlates with previous reports showing decreased levels of this
enzyme in cerebrospinal fluid (CSF) during inflammatory pro-
cesses (Nagai et al., 2000). In CSF of multiple sclerosis patients,
the levels of cystatin C were decreased compared to healthy
controls (Irani et al., 2006); while in CSF of patients with
Alzheimer's or Creutzfeldt–Jakob diseases, cystatin C were
increased (Carrette et al., 2003; Sanchez et al., 2004). Taking this
together we postulate that the mechanism regulating cystatin C
expression is modulated in a disease specific manner rather than
Fig. 4. Quantitative changes in expression of 9 proteins (HIVp24, cystatin B, cystatin C, cofilin-1, L-plastin, SOD, LTA4H, α-enolase, and HCgp-39) in culture
supernatants of HIV-1ADA-infected MDM. Graphs represent densitometric measurements of Western blots and are expressed as log10-transformed value of change
compared to the corresponding control. Statistically significant differences (P<0.05) in levels of expression are marked with an asterisk (*).
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macrophage in the brain. This might be indicative of a
compensatory response of macrophage to ongoing productive
HIV-1 infection and subsequent inflammation. HC-gp39 is a 42-
kDa glycoprotein secreted by articular chondrocytes, synovio-
cytes and macrophages found to play a role in modulation of
cytokine responses following TNF-α and IL-1 stimulation.
Therefore, decreased expression of HC-gp39 may lead to
enhancement of pro-inflammatory effects and profound toxi-
cities. Leukotrienes are made predominantly by polymorpho-
nuclear leukocytes, macrophages, and mast cells. LTA4H
catalyzes the hydrolysis of leukotriene A4 (LTA4) into leuko-
triene B4 (LTB4). LTB4 is a lipid mediator with roles in immune
defense, inflammation, and disease. It is a potent chemoattrac-
tant and mediator of inflammation (Funk, 2001), stimulator of
adhesion to endothelium (Tonnesen et al., 1989), and degranula-
tion (Dahlen et al., 1981). It also stimulates generation of
superoxide anion (Claesson and Feinmark, 1984) and phagocy-
tosis. Overproduced LTB4 contributes to the pathogenesis of a
variety of inflammatory disorders (Goetzl et al., 1995).
It is intriguing that cellular proteins, such as cofilin-1 and L-
plastin, are found secreted by HIV-1-infected macrophages.Cofilin-1 was not detected or detected at very low levels in
culture fluids of control MDM and is present in significant levels
in culture supernatants of infected counterparts. Ott (2002) pos-
tulated that structural proteins, such as actin, cofilin, ezrin, and
moesin are involved in virus assembly and budding, are carried
specifically with viral particles, and were not found in vesicles.
An H9 T-cell lymphoma cell line was used as a model for these
studies in which virus is released by budding from cell
membrane. In our studies, MDMwere used where virus budding
occurs through the exosomal pathway (Nguyen et al., 2003).
Both studies indicate that cofilin-1 is involved in viral assembly
and budding suggests that although virus release has different
pathways, there are common but yet unknown elements
regulating this process. Inhibition of viral assembly utilizing
such elements can be used for targeting both types of cells in
which HIV-1 replicates.
Presented work provides a systematic proteomic approach
leading to a better understanding of the impact of HIV-1 on
regulation of MP, which are critical components of innate
immunity. In a previously published study of macrophage secre-
tome using 2-dimensional electrophoresis and MALDI–TOF
protein fingerprinting, the authors reported 66 identifications
206 P. Ciborowski et al. / Virology 363 (2007) 198–209based on accession numbers; but many of these identifications
were duplicates such as actin, serum albumin, apolipoproteins,
etc. (Dupont et al., 2004). In our current study, we did not find all
previously reported proteins; however, we found proteins that
were not reported by Dupont et al. (2004). It is important to note
that our validation Western blot analyses showed significant and
important differences in expression of several proteins which
were identified in samples from infected and control MDM.
Identification of functional roles of proteins, which seems to be
typical cytoplasmic such asα-enolase and cofilin-1 and which we
found to be at relatively higher levels in the extracellular milieu
due to HIV-1 infection ofMDM,may lead to better understanding
mechanisms of howmacrophage respond to viral infection. These
proteins may have yet unknown functions, specific to extra-
cellular localization, or can be specifically incorporated in HIV-1
particles. Moreover, the fact that proteins belonging to various
classes can be regulated in macrophages following viral infection
highlights the broad range of cellular processes controlled by the
virus.
Proteomic analysis of MDM secretions induced by HIV-1
infection identifies a spectrum of proteins that can be explored
for potential use as a broader panel of biomarkers. Multidi-
mensional fractionation protocols of samples lead to identifica-
tion of constantly increasing number of proteins. Nevertheless,
huge dynamic range of proteins concentrations (Anderson and
Anderson, 2002) and sensitivity of mass spectrometers remain
problems in proteomic studies. Although in this study we did not
detect low abundant proteins such as cytokines and/or
chemokines, we did identify differential regulation of many
proteins that have not been reported in the literature. Determin-
ing whether an individual differentially expressed protein will
serve as a biomarker of an inflammatory process in the brain or
will be a part of a group of biomarkers with value in predicting
clinical outcome will require a larger study using CSF samples
from individuals whose clinical status of neuropathology is well
defined. Such study is currently undergoing in our laboratory.
The application of proteomic approaches is likely to be of
continued importance in studies of macrophage function and
gene regulation leading to a better understanding of disease
processes and the means to combat them.
Materials and methods
Isolation, cultivation, and HIV-1 infection of human MDM
Peripheral blood mononuclear cells were isolated from HIV-
1, 2 and hepatitis seronegative donors by leukophoresis and
purified by countercurrent centrifugal elutriation (Gendelman
et al., 1988). Purified monocytes were cultured in Dulbecco's
modified Eagle medium (DMEM) (Gibco, Carlsbad, CA)
supplemented with 10% heat-inactivated pooled human
serum, 1% glutamine, 50 μg/ml gentamicin (Sigma Chemical
Co., St. Louis, MO), 10 μg/ml ciprofloxacin (Sigma) and
1000 U/ml highly purified recombinant human macrophage
colony stimulating factor (MCSF; a generous gift from
Wyeth, Inc., Cambridge, MA). Cells were maintained at
37 °C with 5% CO2 and half medium exchange was per-formed every 2 days. After 7 days in culture, MDM were
infected with HIV-1ADA at a multiplicity of infection of 0.1 or
left uninfected as controls. Cells were exposed to viral stock
for 4 h at 1/5 of the total medium volume followed by an
additional incubation time of 20 h in full volume of the
medium. After 24 h of exposure to viral stock, inoculum was
removed, cells were washed twice, and fresh full medium was
added to the cultures. 24 h prior to media collection for
proteomic analyses, full medium was removed, cells were
rinsed twice with PBS, and freshly prepared serum-free
DMEM was added to the cultures (Ciborowski et al., 2004;
Ghorpade et al., 2001).
Cytopathicity
To determine levels of cytopathicity by determining the GCI
in HIV-1-infected MDM, monocytes were cultured in 4-well
Lab-Tech chamber slides (Invitrogen, Carlsbad, CA) and treated
as adherent cultures described above. Giemsa staining was
performed on HIV-1ADA-infected and control MDM according
to the manufacturer's protocol (Fisher Scientific, Pittsburgh,
PA) to assess the number of nuclei per cells.
Sample processing
Collected culture fluids were centrifuged at 6000×g for
10 min to remove any detached cells which might be collected
with the fluids. Such prepared culture supernatants were
supplemented with a cocktail of protease inhibitors (Sigma,
St. Louis, MO) and 0.1% Triton X-100 (Fisher Scientific,
Pittsburgh, PA). For reverse transcriptase activity measure-
ments, aliquots of culture supernatants were set aside without
adding detergent and inhibitors. Protein concentrations were
determined using Bio-Rad DC Protein Assay (Bio-Rad,
Hercules, CA) and then samples were concentrated to ∼2 mg/
ml with an Ultrafree-CL centrifugal filter device with 5000 Da
cutoff membrane (Millipore Corporation, Bedford, MA) unless
stated otherwise. Concentrated supernatants were dialyzed 18 h
against water at 4 °C using QuixSep® micro dialyzers (Mem-
brane Filtration Products Inc., Seguin, TX) and protein concen-
trations were measured again using a Bio-Rad DC Protein
Assay.
Multiple affinity column, 4.6×50 mm Hu-6 (Agilent
Technologies, Inc., Santa Clara, CA) was used to remove the
six most abundant proteins (serum albumin, IgG, antitrypsin,
IgA, transferrin, and haptoglobin) from concentrated culture
supernatants following manufacturer recommendations. Briefly,
700 μl of concentrated culture supernatant was mixed with buffer
A and loaded onto the column. A flow through fraction was
collected and column was regenerated using buffer B. To collect
sufficient amounts of protein for analysis, a total amount of
2.1 ml (3 injections, 700 μl each) was processed for each sample.
Measures of RT activity
RT measured levels measured the numbers of progeny virus
and is reflective of productive viral replication. RT activity was
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consisting of 0.05% Nonidet P-40 (Sigma), 10 μg/ml poly(A)
oligonucleotide, 0.25 μg/ml oligo(dT) (Amersham Pharmacia
Biotech, Piscataway, NJ), 5 mM dithiothreitol (Amersham
Pharmacia), 150 mM KCl, 15 mM MgCl2, and 10 μCi/ml [
3H]
dTTP (Perkin Elmer, Wellesley, MA) in 50 mM Tris–HCl
buffer (pH 7.9) was incubated with samples for 18 h at 37 °C.
Radiolabeled nucleotides were precipitated with cold 10%
trichloroacetic acid and 95% ethanol using an automatic cell
harvester (Skatron Inc., Sterling, VA) and were quantitated by
liquid scintillation spectroscopy (Kalter et al., 1991).
One-dimensional electrophoresis (1-DE) and Western blot
assays
1-DE SDS–PAGE separations were performed using BioRad
Proteome IIxi system and 4–20% gradient gel. For sequencing,
a sample of 200 μg of denatured and reduced proteins were
loaded per lane. Gels were stained with Brilliant Blue G-
Colloidal Coomassie (Sigma), de-stained following the protocol
provided by the manufacturer, and digitized using a Typhoon
9410 Phosphoimager (Amersham Biosciences). For Western
blot analyses, 5 to 25 μg of protein was loaded per lane of 4–
12% NuPAGE gel (Invitrogen, Carlsbad, CA). Electrophoresis
followed by transfer and immunodetection was performed as
previously described (Ciborowski et al., 2004).
Antibodies
The following primary antibodies were those directed
against cystatin B (Biovision, Mountain View, CA), HIV-1
p24 (DakoCytomation, Carpinteria, CA), cystatin C (U.S.
Biological, Swampscott, MA), HC-gp39 (R&D Systems,
Minneapolis, MN), cofilin-1 (BD Transduction Laboratories,
Lexington, KY), L-plastin (Biovision), SOD (Calbiochem, La
Jolla, CA), leukotriene A4 hydrolase (Cayman Chemical, Ann
Arbor, MI), and α-enolase (Santa Cruz, Santa Cruz, CA).
Secondary antibodies included HRP-conjugated F(ab′)2 frag-
ment of Goat anti-Mouse Fcγ and Cy5-conjugated F(ab′)2
fragment of Donkey anti-Mouse IgG (Jackson Immunore-
search, West Grove, PA), HRP-conjugated anti-Rabbit IgG
(Cell Signaling Technology, Beverly, MA), and HRP-conju-
gated anti-goat IgG and HRP-conjugated anti-Sheep IgG (U.S.
Biological). All antibodies were used at concentrations recom-
mended by manufacturers.
In-gel trypsin digestion
Gel pieces excised from 1-DE were cut into 20 fragments
and de-stained at room temperature using 200 μl 50% ACN/
50 mM NH4HCO3 for 1 h. Gel pieces were dried, and 1 μg
trypsin in 50 mM NH4HCO3 buffer (Promega, Madison, WI)
was added to each piece. Tryptic digestion was carried out
overnight at 37 °C. Peptides were extracted by washing gel
pieces twice with 60% acetonitrile and 0.1% trifluoroacetic
acid, transferred to clean vials, dried, and re-suspended in
12 μl of water with 0.1% formic acid for mass spectrometricanalysis. All samples were purified using ZipTip® (Millipore
Corporation) prior to mass spectrometric analysis.
ESI–LC–tandem mass spectrometry and search parameters
Samples of in-gel trypsin-digested proteins were fractionated
on microcapillary RP-C18 column (NewObjectives, Woburn,
MA) and the resulting peptides were sequenced using ESI–LC–
MS/MS system (ProteomeX System with LCQDecaPlus mass
spectrometer, ThermoElectron, Inc., San Jose, CA) with a nano-
spray configuration. The spectra obtained from LC–MS/MS
analysis were searched against the NCBI.fasta protein database
narrowed to a subset of human proteins using Sequest search
engine (BioWorks 3.1SR software from ThermoElectron, Inc.).
In the TurboSEQUEST Search Parameters, Threshold for Dta
generation was 10000, Precursor Mass Tolerance for .Dta
Generation was 1.4. For .Dta Search, Peptide Tolerance was 1.5
and Fragment Ions Tolerance was 0.00. Charge state was set on
“Auto”. Database nr.fasta was retrieved from ftp.ncbi.nih.gov
and used to create “in-house” an indexed human.fasta.idx with
the following 5 key words: Homo, sapiens, human, man,
primate and excluding keratins and cytokeratins. We have
excluded keratins from our database search based on observa-
tions that these proteins can be just contaminants acquired
during gels and samples processing. Database was updated
every other week throughout of this study. Oxidated methionine
was allowed in searches.
Densitometry and statistical analyses
Differential expression of 9 proteins was analyzed by
Western blot (WesternPico, Pierce, Inc. Rockford, IL) and
results were transformed into numerical values using densito-
metry measurement of X-ray films. Densitometry was
performed using ImageQuant 5.2 (GE Healthcare, Inc.).
Samples were from 3 donors, in infected and control samples
on days 1, 3, 5 7, and 10. Sample from one donor was
measured twice and the results were averaged and treated as
one biologic replicate for analysis. Data was normalized from
each analysis by taking the fold change as infected/control on
each day for each experiment. The data was then transformed
on the log10 scale so that a ratio of 1 on the original scale
becomes 0 on the log10 scale, ratios greater than 1 are then
positive numbers on the log10 scale and ratios less than 1 are
negative on the log10 scale. The experiments from five donors
were then averaged giving one set of values to be analyzed.
One-sample t-tests were then used to compare the average
log10(ratio) to 0 for each day. P-values less than 0.05 are
considered to be statistically significant.
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